Ortho licenses Agen's D-dimer heart attack test
This article was originally published in Clinica
Executive Summary
Australian company Agen has licensed its D-dimer blood clot tests to Ortho Diagnostic Systems on a non-exclusive basis. The test is based on the DD3B6/22 monoclonal antibody which, like the Washington soluble fibrinogen test, recognises the signs of clot degradation. Announcing the deal just one day after the ACC meeting, Agen's managing director, Roman Zwolenski, said: "The worldwide D-dimer testing market is estimated to be worth US$45 million, and growing significantly." This is Agen's second licence agreement since the European Patent Office upheld its D-dimer patent. Agen is collaborating on the development of an instrument for rapid heart attack testing with US company Source Scientific.